AOC Program

About Avidity Biosciences

Avidity Biosciences is revolutionizing RNA therapeutics through its proprietary AOC platform, which enables targeted delivery to previously inaccessible tissues and cell types. The company's lead programs address the root causes of rare muscle diseases, with clinical data reported for DM1, FSHD, and DMD. As a publicly traded company with an $11.2 billion market valuation, Avidity represents a significant player in the emerging RNA therapeutics space, leveraging proven antibody and oligonucleotide technologies to create first-in-class treatments for underserved patient populations.

About Avidity Biosciences

Avidity Biosciences is revolutionizing RNA therapeutics through its proprietary AOC platform, which enables targeted delivery to previously inaccessible tissues and cell types. The company's lead programs address the root causes of rare muscle diseases, with clinical data reported for DM1, FSHD, and DMD. As a publicly traded company with an $11.2 billion market valuation, Avidity represents a significant player in the emerging RNA therapeutics space, leveraging proven antibody and oligonucleotide technologies to create first-in-class treatments for underserved patient populations.

About Avidity Biosciences

Avidity Biosciences is revolutionizing RNA therapeutics through its proprietary AOC platform, which enables targeted delivery to previously inaccessible tissues and cell types. The company's lead programs address the root causes of rare muscle diseases, with clinical data reported for DM1, FSHD, and DMD. As a publicly traded company with an $11.2 billion market valuation, Avidity represents a significant player in the emerging RNA therapeutics space, leveraging proven antibody and oligonucleotide technologies to create first-in-class treatments for underserved patient populations.

Therapeutic Areas

Other Myotonic Dystrophy Type 1 (DM1) Drugs